[HTML][HTML] Target therapy in thyroid cancer: current challenge in clinical use of tyrosine kinase inhibitors and management of side effects
I Puliafito, F Esposito, A Prestifilippo… - Frontiers in …, 2022 - frontiersin.org
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
I Puliafito, F Esposito, A Prestifilippo… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects.
I Puliafito, F Esposito, A Prestifilippo… - Frontiers in …, 2022 - europepmc.org
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
[PDF][PDF] Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
I Puliafito, F Esposito, A Prestifilippo… - Front. Endocrinol. 13 …, 2022 - academia.edu
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
[HTML][HTML] Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
I Puliafito, F Esposito, A Prestifilippo… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …